Perrigo Company plc (NYSE:PRGO – Get Free Report) was the target of a large decrease in short interest in February. As of February 28th, there was short interest totalling 4,570,000 shares, a decrease of 15.1% from the February 13th total of 5,380,000 shares. Currently, 3.4% of the shares of the stock are sold short. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is presently 2.9 days.
Perrigo Stock Performance
Shares of NYSE PRGO opened at $27.83 on Wednesday. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of -23.78 and a beta of 0.48. The company has a current ratio of 2.56, a quick ratio of 1.77 and a debt-to-equity ratio of 0.94. Perrigo has a 1-year low of $23.14 and a 1-year high of $33.46. The stock’s 50-day moving average is $25.53 and its 200 day moving average is $26.16.
Perrigo (NYSE:PRGO – Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.01. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. On average, sell-side analysts anticipate that Perrigo will post 2.56 EPS for the current fiscal year.
Perrigo Increases Dividend
Analyst Ratings Changes
PRGO has been the topic of several research reports. StockNews.com cut shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Piper Sandler downgraded shares of Perrigo from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $34.00 to $27.00 in a report on Monday, January 6th. Finally, Argus downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a report on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Perrigo has a consensus rating of “Hold” and a consensus price target of $33.00.
Check Out Our Latest Analysis on PRGO
Insiders Place Their Bets
In other Perrigo news, EVP Ronald Craig Janish sold 7,800 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $27.44, for a total value of $214,032.00. Following the sale, the executive vice president now directly owns 33,666 shares in the company, valued at $923,795.04. This represents a 18.81 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.70% of the company’s stock.
Hedge Funds Weigh In On Perrigo
Large investors have recently bought and sold shares of the stock. Headlands Technologies LLC increased its stake in Perrigo by 1,942.0% in the 4th quarter. Headlands Technologies LLC now owns 1,409 shares of the company’s stock worth $36,000 after purchasing an additional 1,340 shares during the period. Versant Capital Management Inc purchased a new position in Perrigo in the 4th quarter worth approximately $45,000. GAMMA Investing LLC increased its stake in Perrigo by 93.7% in the 4th quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $49,000 after purchasing an additional 929 shares during the period. Central Pacific Bank Trust Division increased its stake in shares of Perrigo by 33.3% during the fourth quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company’s stock valued at $51,000 after buying an additional 500 shares during the period. Finally, Venturi Wealth Management LLC increased its stake in shares of Perrigo by 97.8% during the fourth quarter. Venturi Wealth Management LLC now owns 4,215 shares of the company’s stock valued at $108,000 after buying an additional 2,084 shares during the period. 95.91% of the stock is owned by hedge funds and other institutional investors.
About Perrigo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Further Reading
- Five stocks we like better than Perrigo
- What Are Dividend Contenders? Investing in Dividend Contenders
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 Must-Own Stocks to Build Wealth This Decade
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.